{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T23:52:05Z","timestamp":1787701925037,"version":"build-2784847793"},"reference-count":83,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:00:00Z","timestamp":1736812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Telomerase reverse transcriptase (TERT) is the catalytic subunit of the telomerase enzyme responsible for telomere length maintenance and is an important cancer hallmark. Our study aimed to clarify the mRNA expression of TERT in peritoneal mesothelioma (PeM), and to explore the relationship between its expression and the clinicopathological parameters and prognosis of patients with PeM. Methods: In a cohort of 13 MpeM patients, we evaluated histotype, nuclear grade, mitotic count, necrosis, inflammation, Ki67, BAP1, MTAP and p16 expression by immunohistochemistry, p16\/CDKN2A status by FISH and TERT mRNA expression by RNAscope. Results: Our results showed several statistical correlations between TERT mRNA-score and other investigated features: (i) a poor positive correlation with BAP1 score (r = 0.06340; p \u2264 0.0001); (ii) a moderate positive correlation with p16 FISH del homo (r = 0.6340; p \u2264 0.0001); (iii) a fair negative correlation with p16 FISH del hetero (r = \u22120.3965; p \u2264 0.0001); a negative poor correlation with MTAP (r = \u22120.2443; p \u2264 0.0001); and (iv) a negative fair correlation with inflammatory infiltrate (r = \u22120.5407; p = 0.0233). Moreover, patients survive for a significantly longer time if they have a low mitotic index adjusted (2\u20134 mitotic figures per 2 mm2) (p \u2264 0.0001), are male (p = 0.0152), lose BAP1 (p = 0.0152), are p16 positive and present no deletion or heterozygous for p16 (p \u2264 0.01). Conclusions: TERT is highly expressed in PeM, but it is not one of the crucial factors in evaluating the prognosis of patients. Nevertheless, the results validate the prognostic significance of the mitotic index, BAP1 loss and p16\/CDKN2A status.<\/jats:p>","DOI":"10.3390\/cancers17020252","type":"journal-article","created":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T06:13:07Z","timestamp":1736835187000},"page":"252","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Analysis of TERT mRNA Levels and Clinicopathological Features in Patients with Peritoneal Mesothelioma"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4810-1201","authenticated-orcid":false,"given":"Antonio","family":"d\u2019Amati","sequence":"first","affiliation":[{"name":"Department of Medicine and Surgery, LUM University, Casamassima, 70010 Bari, Italy"},{"name":"Department of Translational Biomedicine and Neuroscience, University of Bari Medical School, 70124 Bari, Italy"},{"name":"Department of Precision and Regenerative Medicine and Ionian Area, Pathology Unit, University of Bari \u201cAldo Moro\u201d, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9021-4560","authenticated-orcid":false,"given":"Gabriella","family":"Serio","sequence":"additional","affiliation":[{"name":"Department of Precision and Regenerative Medicine and Ionian Area, Pathology Unit, University of Bari \u201cAldo Moro\u201d, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Quaranta","sequence":"additional","affiliation":[{"name":"Department of Precision and Regenerative Medicine and Ionian Area, Pathology Unit, University of Bari \u201cAldo Moro\u201d, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4072-2871","authenticated-orcid":false,"given":"Luigi","family":"Vimercati","sequence":"additional","affiliation":[{"name":"Department of Interdisciplinary Medicine, Occupational Health Unit, University of Bari \u201cAldo Moro\u201d, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelina","family":"De Giorgis","sequence":"additional","affiliation":[{"name":"Department of Translational Biomedicine and Neuroscience, University of Bari Medical School, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loredana","family":"Lorusso","sequence":"additional","affiliation":[{"name":"Department of Translational Biomedicine and Neuroscience, University of Bari Medical School, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8163-2338","authenticated-orcid":false,"given":"Mariella","family":"Errede","sequence":"additional","affiliation":[{"name":"Department of Translational Biomedicine and Neuroscience, University of Bari Medical School, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito","family":"Longo","sequence":"additional","affiliation":[{"name":"Thoracic Oncology Unit, IRCCS Istituto Tumori \u201cGiovanni Paolo II\u201d, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1265-3685","authenticated-orcid":false,"given":"Andrea","family":"Marzullo","sequence":"additional","affiliation":[{"name":"Department of Precision and Regenerative Medicine and Ionian Area, Pathology Unit, University of Bari \u201cAldo Moro\u201d, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4768-8431","authenticated-orcid":false,"given":"Domenico","family":"Ribatti","sequence":"additional","affiliation":[{"name":"Department of Translational Biomedicine and Neuroscience, University of Bari Medical School, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7752-0368","authenticated-orcid":false,"given":"Tiziana","family":"Annese","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, LUM University, Casamassima, 70010 Bari, Italy"},{"name":"Department of Translational Biomedicine and Neuroscience, University of Bari Medical School, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,14]]},"reference":[{"key":"ref_1","first-page":"659","article-title":"Malignant peritoneal mesothelioma: Clinical aspects, and therapeutic perspectives","volume":"31","author":"Boussios","year":"2018","journal-title":"Ann. Gastroenterol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.21037\/tlcr.2019.12.15","article-title":"Peritoneal mesothelioma","volume":"9","author":"Greenbaum","year":"2020","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.5858\/2006-130-1654-PSOHPI","article-title":"Prognostic significance of histomorphologic parameters in diffuse malignant peritoneal mesothelioma","volume":"130","author":"Cerruto","year":"2006","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_4","first-page":"32","article-title":"Peritoneal mesothelioma: A review","volume":"9","author":"Bridda","year":"2007","journal-title":"Med. Gen. Med."},{"key":"ref_5","first-page":"311","article-title":"Malignant peritoneal mesothelioma: Review of 25 patients","volume":"75","author":"Brenner","year":"1981","journal-title":"Am. J. Gastroenterol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/S0399-8320(07)73964-7","article-title":"Malignant peritoneal mesothelioma: Treatment with maximal cytoreductive surgery plus intraperitoneal chemotherapy","volume":"31","author":"Elias","year":"2007","journal-title":"Gastroenterol. Clin. Biol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1245\/s10434-013-3358-y","article-title":"Malignant peritoneal mesothelioma: Prognostic factors and oncologic outcome analysis","volume":"21","author":"Magge","year":"2014","journal-title":"Ann. Surg. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Li, C.Y., Kennedy, T., and Alexander, H.R. (2022). Treatment of Patients with Malignant Peritoneal Mesothelioma. J. Clin. Med., 11.","DOI":"10.3390\/jcm11071891"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"599","DOI":"10.21037\/tlcr.2018.08.03","article-title":"Update on the management of malignant peritoneal mesothelioma","volume":"7","author":"Sugarbaker","year":"2018","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3892\/mco.2023.2627","article-title":"Immunotherapy in malignant peritoneal mesothelioma (Review)","volume":"18","author":"Alaklabi","year":"2023","journal-title":"Mol. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejso.2020.02.011","article-title":"Peritoneal mesothelioma: PSOGI\/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up","volume":"47","author":"Kusamura","year":"2021","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/bjs5.50256","article-title":"Clinical and surgical outcomes of patients with peritoneal mesothelioma discussed at a monthly national multidisciplinary team video-conference meeting","volume":"4","author":"Brandl","year":"2020","journal-title":"BJS Open"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"16848","DOI":"10.18632\/oncotarget.4253","article-title":"Reactive oxygen species a double-edged sword for mesothelioma","volume":"6","author":"Benedetti","year":"2015","journal-title":"Oncotarget"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Karpes, J.B., Shamavonian, R., Dewhurst, S., Cheng, E., Wijayawardana, R., Ahmadi, N., and Morris, D.L. (2023). Malignant Peritoneal Mesothelioma: An In-Depth and Up-to-Date Review of Pathogenesis, Diagnosis, Management and Future Directions. Cancers, 15.","DOI":"10.3390\/cancers15194704"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1038\/s41379-020-0588-y","article-title":"Molecular characterization of diffuse malignant peritoneal mesothelioma","volume":"33","author":"Hung","year":"2020","journal-title":"Mod. Pathol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1038\/s41416-022-01979-0","article-title":"Genomic landscape of pleural and peritoneal mesothelioma tumours","volume":"127","author":"Hiltbrunner","year":"2022","journal-title":"Br. J. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Fortarezza, F., Pezzuto, F., Marzullo, A., Cavone, D., Romano, D.E., d\u2019Amati, A., Serio, G., and Vimercati, L. (2022). Molecular Pathways in Peritoneal Mesothelioma: A Minireview of New Insights. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.823839"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/modpathol.2015.121","article-title":"The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma","volume":"29","author":"Singhi","year":"2016","journal-title":"Mod. Pathol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"101600","DOI":"10.1016\/j.esmoop.2023.101600","article-title":"Molecular alterations and potential actionable mutations in peritoneal mesothelioma: A scoping review of high-throughput sequencing studies","volume":"8","author":"Dietz","year":"2023","journal-title":"ESMO Open"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.mad.2017.04.004","article-title":"Telomere shortening during aging: Attenuation by antioxidants and anti-inflammatory agents","volume":"164","author":"Prasad","year":"2017","journal-title":"Mech. Ageing Dev."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Dratwa, M., Wysoczanska, B., Lacina, P., Kubik, T., and Bogunia-Kubik, K. (2020). TERT-Regulation and Roles in Cancer Formation. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.589929"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of Cancer: New Dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Gaspar, T.B., Sa, A., Lopes, J.M., Sobrinho-Simoes, M., Soares, P., and Vinagre, J. (2018). Telomere Maintenance Mechanisms in Cancer. Genes, 9.","DOI":"10.3390\/genes9050241"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Udutha, S., Taglang, C., Batsios, G., Gillespie, A.M., Tran, M., Ronen, S.M., Ten Hoeve, J., Graeber, T.G., and Viswanath, P. (2023). Telomerase reverse transcriptase induces targetable alterations in glutathione and nucleotide biosynthesis in glioblastomas. bioRxiv.","DOI":"10.1101\/2023.11.14.566937"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e2213","DOI":"10.1038\/cddis.2016.117","article-title":"Nrf2-driven TERT regulates pentose phosphate pathway in glioblastoma","volume":"7","author":"Ahmad","year":"2016","journal-title":"Cell Death Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1093\/neuonc\/noab093","article-title":"Metabolic imaging detects elevated glucose flux through the pentose phosphate pathway associated with TERT expression in low-grade gliomas","volume":"23","author":"Viswanath","year":"2021","journal-title":"Neuro-Oncology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1158\/1078-0432.CCR-21-4418","article-title":"Deuterium Metabolic Imaging Reports on TERT Expression and Early Response to Therapy in Cancer","volume":"28","author":"Batsios","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/jnc.14152","article-title":"Telomerase reverse transcriptase (TERT)\u2014Enhancer of zeste homolog 2 (EZH2) network regulates lipid metabolism and DNA damage responses in glioblastoma","volume":"143","author":"Ahmad","year":"2017","journal-title":"J. Neurochem."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Cangelosi, D., Morini, M., Zanardi, N., Sementa, A.R., Muselli, M., Conte, M., Garaventa, A., Pfeffer, U., Bosco, M.C., and Varesio, L. (2020). Hypoxia Predicts Poor Prognosis in Neuroblastoma Patients and Associates with Biological Mechanisms Involved in Telomerase Activation and Tumor Microenvironment Reprogramming. Cancers, 12.","DOI":"10.3390\/cancers12092343"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41389-017-0011-9","article-title":"The hypoxic tumour microenvironment","volume":"7","author":"Petrova","year":"2018","journal-title":"Oncogenesis"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/mc.23822","article-title":"Methylation, Gene Expression, and Risk Genotypes at the TERT-CLPTM1L Locus in Cervical Cancer","volume":"64","author":"Ramachandran","year":"2025","journal-title":"Mol. Carcinog."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/onc.2015.75","article-title":"Telomerase reverse transcriptase expression protects transformed human cells against DNA-damaging agents, and increases tolerance to chromosomal instability","volume":"35","author":"Fleisig","year":"2016","journal-title":"Oncogene"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Yuan, X., and Xu, D. (2019). Telomerase Reverse Transcriptase (TERT) in Action: Cross-Talking with Epigenetics. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20133338"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1002\/jcp.25607","article-title":"Human Telomerase Reverse Transcriptase (hTERT) Positively Regulates 26S Proteasome Activity","volume":"232","author":"Im","year":"2017","journal-title":"J. Cell Physiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1158\/1078-0432.CCR-20-3044","article-title":"Targeted Therapy of TERT-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy","volume":"27","author":"Chen","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"458","DOI":"10.5483\/BMBRep.2020.53.9.108","article-title":"Implications of telomerase reverse transcriptase in tumor metastasis","volume":"53","author":"Zou","year":"2020","journal-title":"BMB Rep."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.bbrc.2022.11.068","article-title":"Pan-Cancer analysis of TERT and Validation in Osteosarcoma Cell Lines","volume":"639","author":"Xie","year":"2023","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Gao, M., Lin, Y., Liu, X., Zhao, Z., Zhu, Z., Zhang, H., Ban, Y., Bie, Y., He, X., and Sun, X. (2021). TERT Mutation Is Accompanied by Neutrophil Infiltration and Contributes to Poor Survival in Isocitrate Dehydrogenase Wild-Type Glioma. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.654407"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s40139-015-0087-x","article-title":"Telomere and Telomerase in Carcinogenesis: Their Role as Prognostic Biomarkers","volume":"3","author":"Giunco","year":"2015","journal-title":"Curr. Pathobiol. Rep."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e2323500","DOI":"10.1001\/jamanetworkopen.2023.23500","article-title":"Facilitation of Definitive Cancer Diagnosis With Quantitative Molecular Assays of BRAF V600E and TERT Promoter Variants in Patients With Thyroid Nodules","volume":"6","author":"Fu","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/DAD.0000000000002357","article-title":"PRAME Immunohistochemical Expression and TERT Promoter Mutational Analysis as Ancillary Diagnostic Tools for Differentiating Proliferative Nodules From Melanoma Arising in Congenital Nevi","volume":"45","author":"Boutko","year":"2023","journal-title":"Am. J. Dermatopathol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"102201","DOI":"10.1016\/j.labinv.2024.102201","article-title":"The Molecular Landscape of 227 Adult Granulosa Cell Tumors of the Ovary: Insights into the Progression from Primary to Recurrence","volume":"105","author":"Michalkova","year":"2024","journal-title":"Lab. Investig."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/bjc.2012.602","article-title":"Telomerase is an independent prognostic marker of overall survival in patients with colorectal cancer","volume":"108","author":"Bertorelle","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1038\/bjc.2017.492","article-title":"The predictive and prognostic potential of plasma telomerase reverse transcriptase (TERT) RNA in rectal cancer patients","volume":"118","author":"Rampazzo","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e18953","DOI":"10.1016\/j.heliyon.2023.e18953","article-title":"pTERT C250T mutation: A potential biomarker of poor prognosis in metastatic melanoma","volume":"9","author":"Ruano","year":"2023","journal-title":"Heliyon"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jtho.2021.12.014","article-title":"The 2021 WHO Classification of Tumors of the Pleura: Advances Since the 2015 Classification","volume":"17","author":"Sauter","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/j.1365-2559.2011.04108.x","article-title":"High Wilms\u2019 tumour gene (WT1) expression and low mitotic count are independent predictors of survival in diffuse peritoneal mesothelioma","volume":"60","author":"Scattone","year":"2012","journal-title":"Histopathology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1097\/JTO.0000000000000630","article-title":"The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification","volume":"10","author":"Travis","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00428-008-0689-3","article-title":"Prognostic significance of p16\/cdkn2a loss in pleural malignant mesotheliomas","volume":"453","author":"Dacic","year":"2008","journal-title":"Virchows. Arch."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41379-019-0310-0","article-title":"MTAP immunohistochemistry is an accurate and reproducible surrogate for CDKN2A fluorescence in situ hybridization in diagnosis of malignant pleural mesothelioma","volume":"33","author":"Chapel","year":"2020","journal-title":"Mod. Pathol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.lungcan.2016.12.017","article-title":"Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: Comparison with 9p21 FISH and BAP1 immunohistochemistry","volume":"104","author":"Hida","year":"2017","journal-title":"Lung Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Pezzuto, F., Serio, G., Fortarezza, F., Scattone, A., Caporusso, C., Punzi, A., Cavone, D., Pennella, A., Marzullo, A., and Vimercati, L. (2020). Prognostic Value of Ki67 Percentage, WT-1 Expression and p16\/CDKN2A Deletion in Diffuse Malignant Peritoneal Mesothelioma: A Single-Centre Cohort Study. Diagnostics, 10.","DOI":"10.3390\/diagnostics10060386"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/modpathol.2015.65","article-title":"BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations","volume":"28","author":"Cigognetti","year":"2015","journal-title":"Mod. Pathol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e240058","DOI":"10.1530\/ERC-24-0058","article-title":"Distinct transcriptional and prognostic impacts of TERT promoter mutations C228T and C250T in papillary thyroid carcinoma","volume":"31","author":"Marczyk","year":"2024","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"E754","DOI":"10.1210\/jc.2013-3734","article-title":"TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas","volume":"99","author":"Melo","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"9138","DOI":"10.1200\/JCO.2005.00.562","article-title":"High telomerase RNA expression level is an adverse prognostic factor for favorable-histology Wilms\u2019 tumor","volume":"23","author":"Dome","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"463","DOI":"10.2147\/OTT.S461430","article-title":"Different Role of TRF1 and TRF2 Expression in Non-Small Cell Lung Cancers","volume":"17","author":"Chae","year":"2024","journal-title":"OncoTargets Ther."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1158\/0008-5472.CAN-19-3068","article-title":"Telomere Maintenance Mechanisms Define Clinical Outcome in High-Risk Neuroblastoma","volume":"80","author":"Koneru","year":"2020","journal-title":"Cancer Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s40291-021-00570-2","article-title":"Evaluation of the Suitability of RNAscope as a Technique to Measure Gene Expression in Clinical Diagnostics: A Systematic Review","volume":"26","author":"Atout","year":"2022","journal-title":"Mol. Diagn. Ther."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/978-1-0716-2217-9_10","article-title":"RNAscope for VEGF-A Detection in Human Tumor Bioptic Specimens","volume":"2475","author":"Annese","year":"2022","journal-title":"Methods. Mol. Biol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00418-019-01834-z","article-title":"RNAscope dual ISH-IHC technology to study angiogenesis in diffuse large B-cell lymphomas","volume":"153","author":"Annese","year":"2020","journal-title":"Histochem. Cell Biol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s10735-018-9777-0","article-title":"VEGFA and VEGFR2 RNAscope determination in gastric cancer","volume":"49","author":"Tamma","year":"2018","journal-title":"J. Mol. Histol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"153892","DOI":"10.1016\/j.prp.2022.153892","article-title":"Evaluation of TERT mRNA expression using RNAscope(R): A potential histopathologic diagnostic and prognostic tool","volume":"233","author":"Yousefi","year":"2022","journal-title":"Pathol. Res. Pract."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1038\/ncb2621","article-title":"Telomerase directly regulates NF-kappaB-dependent transcription","volume":"14","author":"Ghosh","year":"2012","journal-title":"Nat. Cell Biol."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Xue, H., Hu, Z., Liu, S., Zhang, S., Yang, W., Li, J., Yan, C., Zhang, J., Zhang, J., and Lei, X. (2024). The mechanism of NF-kappaB-TERT feedback regulation of granulosa cell apoptosis in PCOS rats. PLoS ONE, 19.","DOI":"10.21203\/rs.3.rs-4003002\/v1"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1038\/s41418-023-01149-6","article-title":"Telomerase deficiency and dysfunctional telomeres in the lung tumor microenvironment impair tumor progression in NSCLC mouse models and patient-derived xenografts","volume":"30","author":"Bosso","year":"2023","journal-title":"Cell Death Differ."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nrclinonc.2016.67","article-title":"A second chance for telomerase reverse transcriptase in anticancer immunotherapy","volume":"14","author":"Zanetti","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"115035","DOI":"10.1016\/j.celrep.2024.115035","article-title":"The absence of telomerase leads to immune response and tumor regression in zebrafish melanoma","volume":"43","author":"Nabais","year":"2024","journal-title":"Cell Rep."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1474-9726.2010.00551.x","article-title":"A mutant telomerase defective in nuclear-cytoplasmic shuttling fails to immortalize cells and is associated with mitochondrial dysfunction","volume":"9","author":"Kovalenko","year":"2010","journal-title":"Aging Cell"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"pgad046","DOI":"10.1093\/pnasnexus\/pgad046","article-title":"Transcriptional analysis links B cells and TERT expression to favorable prognosis in head and neck cancer","volume":"2","author":"Xian","year":"2023","journal-title":"PNAS Nexus"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/s41379-020-00688-4","article-title":"Malignant peritoneal mesothelioma: Prognostic significance of clinical and pathologic parameters and validation of a nuclear-grading system in a multi-institutional series of 225 cases","volume":"34","author":"Chapel","year":"2021","journal-title":"Mod. Pathol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13000-021-01125-z","article-title":"Evaluation of prognostic histological parameters proposed for pleural mesothelioma in diffuse malignant peritoneal mesothelioma. A short report","volume":"16","author":"Pezzuto","year":"2021","journal-title":"Diagn. Pathol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.21037\/tlcr.2019.11.11","article-title":"Epidemiology of mesothelioma in the 21(st) century in Europe and the United States, 40 years after restricted\/banned asbestos use","volume":"9","author":"Alpert","year":"2020","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1097\/COC.0000000000000745","article-title":"Gender Differences in Outcomes of Patients With Mesothelioma","volume":"43","author":"Alpert","year":"2020","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1183\/09031936.00000811","article-title":"Predicting survival in malignant mesothelioma","volume":"38","author":"Musk","year":"2011","journal-title":"Eur. Respir. J."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jtho.2016.12.019","article-title":"BAP1 Is Altered by Copy Number Loss, Mutation, and\/or Loss of Protein Expression in More Than 70% of Malignant Peritoneal Mesotheliomas","volume":"12","author":"Leblay","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/carcin\/bgu227","article-title":"Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival","volume":"36","author":"Baumann","year":"2015","journal-title":"Carcinogenesis"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/PAS.0000000000000529","article-title":"Utility of BAP1 Immunohistochemistry and p16 (CDKN2A) FISH in the Diagnosis of Malignant Mesothelioma in Effusion Cytology Specimens","volume":"40","author":"Hwang","year":"2016","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Rossi, G., Righi, L., Barbisan, F., Tiseo, M., Spagnolo, P., Grosso, F., Pisapia, P., Malapelle, U., Sculco, M., and Dianzani, I. (2024). BAP1 Loss, Nuclear Grading, and Nonepithelioid Features in the Diagnosis of Mesothelioma in Italy: Nevermore without the Pathology Report. J. Pers. Med., 14.","DOI":"10.3390\/jpm14040394"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Kotiyal, S., and Evason, K.J. (2021). Exploring the Interplay of Telomerase Reverse Transcriptase and beta-Catenin in Hepatocellular Carcinoma. Cancers, 13.","DOI":"10.3390\/cancers13164202"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.jhep.2020.11.052","article-title":"Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target","volume":"74","author":"Ningarhari","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1158\/1078-0432.CCR-04-1884","article-title":"P16 loss and mitotic activity predict poor survival in patients with peritoneal malignant mesothelioma","volume":"11","author":"Borczuk","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.1016\/j.cell.2024.05.048","article-title":"TERT activation targets DNA methylation and multiple aging hallmarks","volume":"187","author":"Shim","year":"2024","journal-title":"Cell"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/2\/252\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:28:33Z","timestamp":1759919313000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/2\/252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,14]]},"references-count":83,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["cancers17020252"],"URL":"https:\/\/doi.org\/10.3390\/cancers17020252","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,14]]}}}